Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Pulmonary fibrosis: “idiopathic” is not “cryptogenic”

Athol U. Wells, Kevin K. Brown, Kevin R. Flaherty, Martin Kolb, Victor J. Thannickal on behalf of the IPF Consensus Working Group
European Respiratory Journal 2019 53: 1900400; DOI: 10.1183/13993003.00400-2019
Athol U. Wells
1Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rbhild@rbht.nhs.uk
Kevin K. Brown
2National Jewish Health, Denver, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin R. Flaherty
3University of Michigan Health System, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kolb
4Dept of Respiratory Medicine, Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin Kolb
Victor J. Thannickal
5Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The additional argument advanced by Professor Cottin for retention of the term “idiopathic pulmonary fibrosis” is highly persuasive http://ow.ly/n05630nVCZd

From the authors:

The writer makes a powerful plea for clarity of thought based on clarity of language, arguing from the Socratic maxim that “the beginning of wisdom is the definition of terms”. This etymological perspective is extremely apposite because the distinction between “cryptogenic” and “idiopathic” disease is seminal in the ongoing idiopathic pulmonary fibrosis (IPF) terminology debate.

In our recent perspective [1], we highlighted the dangers of conflating two separate aspects of pathogenesis: the initiation of disease, which may be largely related to epithelial events, and disease progression, which is likely to be influenced by the stromal response that includes fibroblasts and immune cells. Recent advances have largely related to the former and it can be argued, vide Cottin, that based on increasing knowledge of predilections and triggers, IPF is less cryptogenic than it once was: perhaps the origin of the disease is now “obscure” but increasingly less “hidden”. However, the relentless progression of fibrosis in IPF remains, in the words of Sir Winston Churchill, “a riddle, wrapped in a mystery, inside an enigma”: verily, “a disease of its own”. We agree that the term “idiopathic” aptly summarises the conundrum that is IPF progression.

Footnotes

  • The IPF Consensus Working Group: K.M. Antoniou, J. Behr, P.B. Bitterman, C.D. Cool, U. Costabel, T.V. Colby, V. Cottin, B. Crestani, G.P. Downey, J. Gauldie, S.D. Groshong, A. Guenther, J.C. Horowitz, Y. Inoue, J.A. Lasky, A.H. Limper, D.A. Lynch, F.J. Martinez, J.L. Myers, A.G. Nicholson, I. Noth, V. Poletti, C.J. Ryerson, J.H. Ryu, D. Valeyre, C. Vancheri and E.S. White.

  • Conflict of interest: A.U. Wells reports personal fees for consultancy and lecturing from Intermune/Roche, Boehringer Ingelheim and Bayer, and personal fees for consultancy from Gilead, outside the submitted work.

  • Conflict of interest: K.K. Brown reports multiple lung fibrosis grants from NHLBI, personal fees from AstraZeneca, Biogen, Fibrogen, Galecto, Gilead, MedImmune, Novartis, Aeolus, ProMetic, Patara, Third Pole, aTyr, Galapagos and Boehringer Ingelheim, has a submitted grant with Roche/Genentech, and conversation under CDA only with Global Blood Therapeutics and Genoa, outside the submitted work.

  • Conflict of interest: K.R. Flaherty reports grants and personal fees from Boehringer Ingelheim and Roche/Genentech, grants from Afferent, personal fees from Veracyte, Fibrogen, Immuneworks, Aeolus, Pharmakea, Sanofi-genzyme and Celgene, outside the submitted work.

  • Conflict of interest: M. Kolb reports grants and personal fees from Roche, Boehringer Ingelheim, GSK and Prometic, personal fees from Gilead and Genoa, and grants from Actelion, Respivert, Alkermes and Pharmaxis, outside the submitted work.

  • Conflict of interest: V.J. Thannickal has nothing to disclose.

  • Received February 26, 2019.
  • Accepted February 26, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

Reference

  1. ↵
    1. Wells AU,
    2. Brown KK,
    3. Flaherty KR, et al.
    What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51: 1800692.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 53 Issue 3 Table of Contents
European Respiratory Journal: 53 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary fibrosis: “idiopathic” is not “cryptogenic”
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary fibrosis: “idiopathic” is not “cryptogenic”
Athol U. Wells, Kevin K. Brown, Kevin R. Flaherty, Martin Kolb, Victor J. Thannickal
European Respiratory Journal Mar 2019, 53 (3) 1900400; DOI: 10.1183/13993003.00400-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary fibrosis: “idiopathic” is not “cryptogenic”
Athol U. Wells, Kevin K. Brown, Kevin R. Flaherty, Martin Kolb, Victor J. Thannickal
European Respiratory Journal Mar 2019, 53 (3) 1900400; DOI: 10.1183/13993003.00400-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • Reference
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Erythrocytes are altered in PAH
  • Long COVID symptoms, from an imaginary condition to a recognised syndrome
  • NTM-PD incidence among elderly patients with bronchiectasis
Show more Agora

Correspondence

  • Erythrocytes are altered in PAH
  • Long COVID symptoms, from an imaginary condition to a recognised syndrome
  • NTM-PD incidence among elderly patients with bronchiectasis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society